

## **Massachusetts-based company to present at Global Health Care Conference**

**Auburndale, MA., May 26, 2015** -- Advantagene, Inc., a clinical-stage biotechnology company developing a novel cancer immunotherapy platform, announced today that Dr. Estuardo Aguilar, Chairman and Chief Executive Officer, will present advances on their late-stage clinical programs at the 2015 Jefferies Global Healthcare Conference on June 4, 2015, at 11:a.m., in New York, NY.

About Advantagene, Inc.

Advantagene is a Massachusetts based biotechnology company developing its proprietary *Gene Mediated Cytotoxic Immunotherapy (GMCI®)* technology for the treatment of solid tumors. GMCI® is an “off the shelf” low toxicity immunotherapy that stimulates a patient’s own immune system to generate a robust response against his or her cancer, causing tumor cell death and clearance. Advantagene is conducting a registration clinical trial with its lead clinical candidate, ProstAtak®, for the treatment of newly diagnosed prostate cancer patients under a Special Protocol Assessment issued by the U.S. Food and Drug Administration. If approved, ProstAtak® will be the first and only pharmaceutical intervention available for these patients. The company has additional Phase II and Phase I/II clinical studies using GMCI® to treat lung, pancreas and brain cancer with impressive clinical results to date.

For more information about Advantagene and our GMCI® cancer immunotherapy program please visit [www.advantagene.com](http://www.advantagene.com)

### Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advantagene’s plans and ability to develop its GMCI® technology to safely and effectively treat cancer. These forward-looking statements are subject to a number of risks. Advantagene undertakes no obligation to update these forward looking statement and you are cautioned not to place undue reliance on any of these forward-looking statements.